Tuesday, July 1, 2025 7/1/2025

Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application

Award Number: UG1CA233178
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/24/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application - PROJECT SUMMARY/ABSTRACT As a National Cancer Institute (NCI) Network Lead Academic Participating Site (NLAPS), Huntsman Cancer Institute (HCI) provides leadership and robust accruals for the National Clinical Trials Network (NCTN) Program. Building on our prior success with five years of U10-funded NLAPS partner and the last six years of the UG1 grant, HCI NLAPS program will continue to contribute to the development and conduct of clinical trials in collaboration with SWOG, NRG Oncology, and Alliance for Clinical Trials in Oncology (ALLIANCE) NCTN Groups. Additionally, we will ensure substantial accrual to clinical trials across the entire NCTN. The HCI NLAPS executive team is highly qualified and experienced in cooperative group research. Our newly named institutional Principal Investigator (PI), Heloisa Soares, MD, PhD, is a medical oncologist specializing in gastrointestinal and neuroendocrine cancers, with an extensive history of leadership and participation in NCTN activities, including being study chair for NCTN trials and serving in various leadership boards within the LPOs. The new PI transition will involve a few key personnel changes within the NCTN Executive Team and specific Lead Protocol Organizations within the NLAPS. HCI’s faculty significantly contributes to the leadership of the NCTN program through active participation on steering committees, task forces, and group activities. Over the past six years, more than ten HCI faculty members have served as national principal investigators (PIs) or study chairs or co-chairs on NCTN trials. HCI has a strong, established commitment to participating in NCTN trials. To date in calendar year 2024, 13% (76/558) of HCI therapeutic accruals were made to NCTN trials, and consistently, over 60 NCTN therapeutic trials are open to accrual, including rare disease trials. HCI continues to aim to be a key partner to the NCTN in cooperative group research. The culture of our Cancer Center is driven by collaboration, excellence, and innovation. All endeavors at HCI are characterized by our core values: patient first, united effort, and excellence in all we do. We have a robust and comprehensive clinical trials enterprise, excellent commitment from the larger university, dedicated philanthropic support to build our faculty and facilities, and state-of-the-art research infrastructure in basic, clinical, and translational realms. Our Center will leverage these resources toward the success of the NCTN in its cooperative endeavors to eradicate cancer as the only NCI designated center serving the 5 states in the Mountain West. During the NLAPS supplement year, HCI will remain a dedicated and enduring partner to the NCTN program, distinguished by its expertise, leadership, and active participation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $301,967 )
2025	2025	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	002	6	3/10/2025	SUPPLEMENT FOR EXPANSION	$301,967
2025	2024	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	001	6	12/23/2024	NON-COMPETING CONTINUATION	$0
2025	2024	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	000	6	12/5/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $301,967

Issue Date FY: 2024 ( Subtotal = $548,114 )
2024	2024	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	001	6	4/17/2024	NON-COMPETING CONTINUATION	$25,164
2024	2024	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	000	6	2/14/2024	NON-COMPETING CONTINUATION	$452,951
2024	2024	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	002	6	9/6/2024	NON-COMPETING CONTINUATION	$69,999
														Subtotal = $548,114

Issue Date FY: 2023 ( Subtotal = $439,225 )
2023	2023	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	001	5	8/1/2023	NON-COMPETING CONTINUATION	$0
2023	2023	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	000	5	2/16/2023	NON-COMPETING CONTINUATION	$439,225
														Subtotal = $439,225

Issue Date FY: 2022 ( Subtotal = $566,240 )
2022	2022	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	001	4	8/18/2022	NON-COMPETING CONTINUATION	$63,007
2022	2022	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	000	4	3/1/2022	NON-COMPETING CONTINUATION	$503,233
														Subtotal = $566,240

Issue Date FY: 2021 ( Subtotal = $1,132,625 )
2021	2021	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	003	3	8/13/2021	NON-COMPETING CONTINUATION	$0
2021	2021	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	000	2	12/18/2020	SUPPLEMENT FOR EXPANSION	$274,995
2021	2021	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	002	3	2/17/2021	NON-COMPETING CONTINUATION	$502,630
2021	2021	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	001	2	12/24/2020	SUPPLEMENT FOR EXPANSION	$0
2021	2021	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	004	3	9/17/2021	NON-COMPETING CONTINUATION	$355,000
														Subtotal = $1,132,625

Issue Date FY: 2020 ( Subtotal = $603,279 )
2020	2020	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	001	2	2/19/2020	NON-COMPETING CONTINUATION	$503,279
2020	2020	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	000	1	11/27/2019	SUPPLEMENT FOR EXPANSION	$100,000
														Subtotal = $603,279

Issue Date FY: 2019 ( Subtotal = $503,279 )
2019	2019	UNIVERSITY OF UTAH, THE	201 S PRESIDENT CIRCLE RM 408	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Treatment Research	000	1	3/15/2019	NEW	$503,279
														Subtotal = $503,279

Grand Total All Awards = $4,094,729

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application

Award Number: UG1CA233178

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/24/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer